NDAORALTABLET
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ALTACE (ramipril) by Pfizer is animals. First approved in 2007.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTACE (ramipril) is an oral ACE inhibitor tablet approved in 2007 for hypertension and heart failure. It works by inhibiting angiotensin-converting enzyme, reducing angiotensin II formation and decreasing vasopressor activity and aldosterone secretion. The drug is effective across racial groups, though Black patients show a smaller average blood pressure response to monotherapy.
$0.002BPart D
LOE ApproachingDeclining
With LOE approaching and modest Part D spending, the ALTACE brand team is likely in defensive/maintenance mode with limited expansion headcount.
Mechanism of Action
animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II,…
Indications
Worked on ALTACE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.